

# Leteris C Zacharia

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2551209/publications.pdf>

Version: 2024-02-01

50  
papers

2,128  
citations

236925

25  
h-index

233421

45  
g-index

50  
all docs

50  
docs citations

50  
times ranked

2603  
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel Zinc and Vanadium (V) Hydroquinonate Complexes: Synthesis and Biological Solution Evaluation. <i>Journal of Molecular Structure</i> , 2022, 1257, 132582.	3.6	3
2	Ginkgo biloba L. flavonoids inhibit CYP 2A5; potential dietary supplement for nicotine replacement therapy enhancement. <i>Natural Product Research</i> , 2021, , 1-5.	1.8	1
3	Cheminformatics and virtual screening studies of COMT inhibitors as potential Parkinson's disease therapeutics. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 53-62.	5.0	8
4	Computer-Aided Drug Design of $\beta$ -Secretase, $\gamma$ -Secretase and Anti-Tau Inhibitors for the Discovery of Novel Alzheimer's Therapeutics. <i>International Journal of Molecular Sciences</i> , 2020, 21, 703.	4.1	45
5	Depletion of Ras Suppressor-1 (RSU-1) promotes cell invasion of breast cancer cells through a compensatory upregulation of a truncated isoform. <i>Scientific Reports</i> , 2019, 9, 10050.	3.3	10
6	Collagen content and extracellular matrix cause cytoskeletal remodelling in pancreatic fibroblasts. <i>Journal of the Royal Society Interface</i> , 2019, 16, 20190226.	3.4	25
7	On the Issue of the Derivation of Permitted Daily Exposure for the Androgen Receptor Antagonist Flutamide. <i>Toxicological Sciences</i> , 2018, 163, 334-334.	3.1	0
8	Targeting Inflammation to Improve Tumor Drug Delivery. <i>Trends in Cancer</i> , 2017, 3, 621-630.	7.4	28
9	Permitted Daily Exposure of the Androgen Receptor Antagonist Flutamide. <i>Toxicological Sciences</i> , 2017, 159, 279-289.	3.1	7
10	Ras Suppressor-1 (RSU-1) in Cancer Cell Metastasis: Friend or Foe?. <i>Critical Reviews in Oncogenesis</i> , 2017, 22, 249-253.	0.4	11
11	The Ras suppressor-1 (RSU-1) in cancer. <i>Advances in Modern Oncology Research</i> , 2017, 3, 47.	0.1	1
12	Ras suppressor-1 promotes apoptosis in breast cancer cells by inhibiting PINCH-1 and activating p53-upregulated-modulator of apoptosis (PUMA); verification from metastatic breast cancer human samples. <i>Clinical and Experimental Metastasis</i> , 2015, 32, 255-265.	3.3	23
13	Cancer cell metastasis; perspectives from the focal adhesion. <i>Advances in Modern Oncology Research</i> , 2015, 1, 2.	0.1	1
14	Mitogen-inducible Gene-2 (MIG2) and migfilin expression is reduced in samples of human breast cancer. <i>Anticancer Research</i> , 2013, 33, 1977-81.	1.1	9
15	In Vivo Hypoxic Preconditioning Protects From Warm Liver Ischemia-Reperfusion Injury Through the Adenosine A2B Receptor. <i>Transplantation</i> , 2012, 94, 894-902.	1.0	42
16	Resveratrol, a Red Wine Constituent, Blocks the Antimitogenic Effects of Estradiol on Human Female Coronary Artery Smooth Muscle Cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, E9-E17.	3.6	12
17	Cooperation of adenosine and prostaglandin E2 (PGE2) in amplification of cAMP/PKA signaling and immunosuppression. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1611-1623.	4.2	62
18	$\beta$ 2-Adrenoceptors Enhance Angiotensin II-Induced Renal Vasoconstriction. <i>Hypertension</i> , 2008, 51, 719-726.	2.7	27

#	ARTICLE	IF	CITATIONS
19	Medroxyprogesterone Abrogates the Inhibitory Effects of Estradiol on Vascular Smooth Muscle Cells by Preventing Estradiol Metabolism. <i>Hypertension</i> , 2008, 51, 1197-1202.	2.7	11
20	Characterization of Renal Ecto-Phosphodiesterase. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 321, 810-815.	2.5	23
21	The Pancreatohepatorenal cAMP-Adenosine Mechanism. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 321, 799-809.	2.5	15
22	A 1 Adenosine Receptor Upregulation Accompanies Decreasing Myocardial Adenosine Levels in Mice With Left Ventricular Dysfunction. <i>Circulation</i> , 2007, 115, 2307-2315.	1.6	36
23	Medical tourism: Outsourcing surgery. <i>Mathematical and Computer Modelling</i> , 2007, 46, 1144-1159.	2.0	82
24	Adenosine-Mediated Inhibition of the Cytotoxic Activity and Cytokine Production by Activated Natural Killer Cells. <i>Cancer Research</i> , 2006, 66, 7758-7765.	0.9	126
25	Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain $\beta$ -amyloid production. <i>Neuroscience</i> , 2006, 142, 941-952.	2.3	417
26	Conversion of tibolone to $17\beta$ -methyl-ethinyl estradiol using gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry. <i>Menopause</i> , 2006, 13, 926-934.	2.0	9
27	Adenosine receptor expression and function in bladder uroepithelium. <i>American Journal of Physiology - Cell Physiology</i> , 2006, 291, C254-C265.	4.6	65
28	cAMP-Adenosine Pathway in the Proximal Tubule. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 317, 1219-1229.	2.5	41
29	Renal interstitial cAMP and AMP are converted to adenosine: application of a mass spectrometric ion trap assay for purines. <i>FASEB Journal</i> , 2006, 20, A765.	0.5	0
30	Characterization of the Effects of Adenosine Receptor Agonists on Cerebral Blood Flow in Uninjured and Traumatically Injured Rat Brain using Continuous Arterial Spin-Labeled Magnetic Resonance Imaging. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, 1596-1612.	4.3	34
31	Cytochromes 1A1/1B1- and Catechol-O-Methyltransferase-Derived Metabolites Mediate Estradiol-Induced Antimitogenesis in Human Cardiac Fibroblast. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 247-255.	3.6	33
32	Gs Protein-Coupled Adenosine Receptor Signaling and Lytic Function of Activated NK Cells. <i>Journal of Immunology</i> , 2005, 175, 4383-4391.	0.8	145
33	Catecholamines Block the Antimitogenic Effect of Estradiol on Human Coronary Artery Smooth Muscle Cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 3922-3931.	3.6	21
34	2-Hydroxyestradiol Is a Prodrug of 2-Methoxyestradiol. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 309, 1093-1097.	2.5	40
35	Hormone Replacement Therapy and Cardiovascular Disease. <i>Hypertension</i> , 2004, 44, 789-795.	2.7	81
36	A gas chromatography/mass spectrometry assay to measure estradiol, catecholestradiols, and methoxyestradiols in plasma. <i>Steroids</i> , 2004, 69, 255-261.	1.8	27

#	ARTICLE	IF	CITATIONS
37	Methoxyestradiols Mediate the Antimitogenic Effects of 17 $\beta$ -Estradiol. <i>Circulation</i> , 2003, 108, 2974-2978.	1.6	48
38	Methylation of 2-Hydroxyestradiol in Isolated Organs. <i>Hypertension</i> , 2003, 42, 82-87.	2.7	15
39	Catecholamines Block the Antimitogenic Effect of Estradiol on Human Glomerular Mesangial Cells. <i>Hypertension</i> , 2003, 42, 349-355.	2.7	9
40	CYP450- and COMT-Derived Estradiol Metabolites Inhibit Activity of Human Coronary Artery SMCs. <i>Hypertension</i> , 2003, 41, 807-813.	2.7	51
41	Role of Methoxyestradiols in the Growth Inhibitory Effects of Estradiol on Human Glomerular Mesangial Cells. <i>Hypertension</i> , 2002, 39, 418-424.	2.7	50
42	Methoxyestradiols Mediate the Antimitogenic Effects of Locally Applied Estradiol on Cardiac Fibroblast Growth. <i>Hypertension</i> , 2002, 39, 412-417.	2.7	40
43	Methoxyestradiols Mediate Estradiol-Induced Antimitogenesis in Human Aortic SMCs. <i>Hypertension</i> , 2002, 39, 874-879.	2.7	67
44	Catecholamines Block 2-Hydroxyestradiol-Induced Antimitogenesis in Mesangial Cells. <i>Hypertension</i> , 2002, 39, 854-859.	2.7	8
45	A $\beta_2$ Receptors Mediate the Antimitogenic Effects of Adenosine in Cardiac Fibroblasts. <i>Hypertension</i> , 2001, 37, 716-721.	2.7	78
46	Catecholamines Abrogate Antimitogenic Effects of 2-Hydroxyestradiol on Human Aortic Vascular Smooth Muscle Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 1745-1750.	2.4	29
47	Increased 2-Methoxyestradiol Production in Human Coronary Versus Aortic Vascular Cells. <i>Hypertension</i> , 2001, 37, 658-662.	2.7	35
48	Inhibition Of Cytokine Release By And Cardiac Effects Of Type Iv Phosphodiesterase Inhibition In Early, Profound Endotoxaemia In Vivo. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2000, 27, 787-792.	1.9	8
49	Clinically Used Estrogens Differentially Inhibit Human Aortic Smooth Muscle Cell Growth and Mitogen-Activated Protein Kinase Activity. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 964-972.	2.4	92
50	Methoxyestradiols Mediate the Antimitogenic Effects of Estradiol on Vascular Smooth Muscle Cells via Estrogen Receptor-Independent Mechanisms. <i>Biochemical and Biophysical Research Communications</i> , 2000, 278, 27-33.	2.1	77